You have 9 free searches left this month | to do more
Showing 1 - 25 of
>10,000 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
MAP to Provide Access to Ruxolitinib, for Patients With PMF or PPV MF or PET-MF
Available
  • Primary Myelofibrosis (PMF)
  • +2 more
  • (no location specified)
2022-01-18
Jan 18, 2022
I
IMG-7289 in Patients With Myelofibrosis - 2022
Completed
  • Myelofibrosis
  • +3 more
  • Ann Arbor, Michigan
  • +4 more
2022-03-28
Mar 28, 2022
N
Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis - 2020
Completed
  • Idiopathic Myelofibrosis
  • +2 more
  • Paris, France
  • +9 more
2021-06-22
Jun 22, 2021
N
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF - 2020
Completed
Has Results
  • Primary Myelofibrosis
  • +2 more
  • Scottsdale, Arizona
  • +8 more
2022-02-10
Feb 10, 2022
N
Study of Select Combinations in Adults With Myelofibrosis
Withdrawn
  • Primary Myelofibrosis
  • +4 more
  • (no location specified)
2021-03-02
Mar 2, 2021
N
Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis
Not yet recruiting
  • Primary Myelofibrosis
  • +2 more
  • (no location specified)
2021-11-05
Nov 5, 2021
U
Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors
Recruiting
  • Primary Myelofibrosis
  • +2 more
  • Salt Lake City, Utah
    Huntsman Cancer Institute/University of Utah
2021-09-27
Sep 27, 2021
S
Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia - 2018
Completed
Has Results
  • Primary Myelofibrosis
  • +4 more
  • Scottsdale, Arizona
  • +21 more
2021-01-18
Jan 18, 2021
I
Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF) - 2019
Completed
Has Results
  • Myelofibrosis
  • Winter Park, Florida
  • +17 more
2022-01-10
Jan 10, 2022
J
MPN-RC 118 AVID200 in Myelofibrosis
Active, not recruiting
  • Primary Myelofibrosis
  • +4 more
  • New York, New York
    Icahn School of Medicine at Mount Sinai
2021-05-19
May 19, 2021
L
A Study of LNK01002 in Patients With Primary (PMF) or Secondary Myelofibrosis (PV-MF, ET-MF) or Acute Myeloid Leukemia
Recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • Farmington Hills, Michigan
  • +1 more
2021-06-05
Jun 5, 2021
S
Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) - 2017
Completed
Has Results
  • Primary Myelofibrosis (PMF)
  • +2 more
  • Phoenix, Arizona
  • +12 more
2021-01-12
Jan 12, 2021
S
Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib
Recruiting
  • Primary Myelofibrosis (PMF)
  • +2 more
  • Larkspur, California
  • +2 more
2021-09-21
Sep 21, 2021
G
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease - 2017
Terminated
Has Results
  • Myelofibrosis
  • Stanford, California
  • +1 more
2020-08-31
Aug 31, 2020
P
Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis
Recruiting
  • Myelofibrosis
  • Liverpool, New South Wales, Australia
  • +10 more
2021-10-07
Oct 7, 2021
C
A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Recruiting
  • Primary Myelofibrosis
  • Aomori, Japan
  • +15 more
2022-01-19
Jan 19, 2022
N
A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis
Active, not recruiting
  • Primary Myelofibrosis
  • +2 more
  • Jakavi
  • Aachen, Germany
    Novartis Investigative Site
2021-09-06
Sep 6, 2021
N
A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis - 2011
Terminated
Has Results
  • Primary Myelofibrosis
  • +2 more
  • Scottsdale, Arizona
  • +8 more
2021-07-09
Jul 9, 2021
N
A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis - 2017
Terminated
  • Myelofibrosis
  • Herston, Queensland, Australia
  • +14 more
2020-12-16
Dec 16, 2020
C
A Safety Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib With Concomitant Luspatercept for Subjects With Anemia
Recruiting
  • Primary Myelofibrosis
  • +2 more
  • Aurora, Colorado
  • +34 more
2022-02-16
Feb 16, 2022
S
Jaktinib Hydrochloride for the Treatment of Ruxolitinib Intolerance of Myelofibrosis
Recruiting
  • Myelofibrosis
  • +3 more
  • Jaktinib hydrochloride tablets
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital of Medical School of Zhejiang Univ
2021-06-11
Jun 11, 2021
H
A Phase 2 Study of RO7490677 In Participants With Myelofibrosis - 2020
Completed
Has Results
  • Primary Myelofibrosis
  • +2 more
  • Phoenix, Arizona
  • +22 more
2021-12-07
Dec 7, 2021
S
Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF - 2019
Completed
  • Primary Myelofibrosis (PMF)
  • +2 more
  • Los Angeles, California
  • +47 more
2020-04-01
Apr 1, 2020
K
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib
Recruiting
  • Myelofibrosis
  • Duarte, California
  • +32 more
2021-10-27
Oct 27, 2021
C
An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
Recruiting
  • Primary Myelofibrosis
  • +2 more
  • Darlinghurst, New South Wales, Australia
  • +109 more
2022-03-15
Mar 15, 2022